Additionally, randomized controlled trials should evaluate the safety and efficacy of pharmacological interventions, particularly GLP-1 receptor agonists, in fasting individuals with diabetes who also have subclinical or overt gastroparesis. Here, GLP1R is linked to gastroparesis.